317 related articles for article (PubMed ID: 21570710)
1. Malignant melanoma of the vulva: an extension of cutaneous melanoma?
Moxley KM; Fader AN; Rose PG; Case AS; Mutch DG; Berry E; Schink JC; Kim CH; Chi DS; Moore KN
Gynecol Oncol; 2011 Sep; 122(3):612-7. PubMed ID: 21570710
[TBL] [Abstract][Full Text] [Related]
2. Vulvar melanoma: is there a role for sentinel lymph node biopsy?
de Hullu JA; Hollema H; Hoekstra HJ; Piers DA; Mourits MJ; Aalders JG; van der Zee AG
Cancer; 2002 Jan; 94(2):486-91. PubMed ID: 11905414
[TBL] [Abstract][Full Text] [Related]
3. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
4. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
[TBL] [Abstract][Full Text] [Related]
5. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
6. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
7. Malignant melanoma of the vulva.
Jaramillo BA; Ganjei P; Averette HE; Sevin BU; Lovecchio JL
Obstet Gynecol; 1985 Sep; 66(3):398-401. PubMed ID: 4022497
[TBL] [Abstract][Full Text] [Related]
8. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
10. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
13. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
15. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
[TBL] [Abstract][Full Text] [Related]
16. Vulvar melanoma: a multivariable analysis of 644 patients.
Sugiyama VE; Chan JK; Shin JY; Berek JS; Osann K; Kapp DS
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):296-301. PubMed ID: 17666603
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
MandalĂ M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients.
Howman-Giles R; Shaw HM; Scolyer RA; Murali R; Wilmott J; McCarthy SW; Uren RF; Thompson JF
Ann Surg Oncol; 2010 Jan; 17(1):138-43. PubMed ID: 19672660
[TBL] [Abstract][Full Text] [Related]
19. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
20. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]